Company intelligence / Profile preview
Burzynski Research Institute
Houston, Texas, United Statesburzynskiclinic.com ↗
- Ownership
- Public · BZYR
- Development stage
- Other
01
Overview
Burzynski Research Institute is developing investigational cancer therapies called antineoplastons. These have been studied primarily in phase I and II trials for various cancers, especially malignant brain tumors. A randomized phase III trial for diffuse intrinsic brainstem glioma is ongoing as of June 2025. However, there is no robust independent evidence supporting efficacy; most positive results come from within the organization itself. No FDA-approved products exist to date.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculePeptides
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Financials
- Market cap
- $26.3K
- Total revenue
- $0
- Enterprise value
- $24.1K
Beyond the preview
Go deeper on Burzynski Research Institute.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Burzynski Research Institute.